nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—SLC6A4—Alzheimer's disease	0.284	0.587	CbGaD
Methylphenidate—CYP2D6—Alzheimer's disease	0.2	0.413	CbGaD
Methylphenidate—CYP2D6—Rivastigmine—Alzheimer's disease	0.102	0.432	CbGbCtD
Methylphenidate—CYP2D6—Donepezil—Alzheimer's disease	0.0817	0.345	CbGbCtD
Methylphenidate—CYP2D6—Galantamine—Alzheimer's disease	0.0526	0.223	CbGbCtD
Methylphenidate—SLC6A2—locus ceruleus—Alzheimer's disease	0.00987	0.298	CbGeAlD
Methylphenidate—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.0058	0.175	CbGeAlD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—KLK6—Alzheimer's disease	0.0018	0.0611	CbGpPWpGaD
Methylphenidate—SLC6A3—forebrain—Alzheimer's disease	0.00151	0.0458	CbGeAlD
Methylphenidate—SLC6A3—telencephalon—Alzheimer's disease	0.00139	0.0421	CbGeAlD
Methylphenidate—SLC6A4—forebrain—Alzheimer's disease	0.00139	0.042	CbGeAlD
Methylphenidate—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—ACHE—Alzheimer's disease	0.0013	0.0441	CbGpPWpGaD
Methylphenidate—SLC6A4—telencephalon—Alzheimer's disease	0.00128	0.0386	CbGeAlD
Methylphenidate—SLC6A2—forebrain—Alzheimer's disease	0.00122	0.0369	CbGeAlD
Methylphenidate—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—Alzheimer's disease	0.00113	0.0384	CbGpPWpGaD
Methylphenidate—SLC6A2—telencephalon—Alzheimer's disease	0.00112	0.034	CbGeAlD
Methylphenidate—SLC6A4—Synaptic Vesicle Pathway—SYP—Alzheimer's disease	0.00102	0.0347	CbGpPWpGaD
Methylphenidate—SLC6A4—Synaptic Vesicle Pathway—SLC18A3—Alzheimer's disease	0.000833	0.0283	CbGpPWpGaD
Methylphenidate—SLC6A3—nervous system—Alzheimer's disease	0.000822	0.0249	CbGeAlD
Methylphenidate—SLC6A3—central nervous system—Alzheimer's disease	0.000792	0.0239	CbGeAlD
Methylphenidate—SLC6A3—cerebellum—Alzheimer's disease	0.000774	0.0234	CbGeAlD
Methylphenidate—SLC6A4—nervous system—Alzheimer's disease	0.000753	0.0228	CbGeAlD
Methylphenidate—SLC6A4—Monoamine Transport—PVRL2—Alzheimer's disease	0.000751	0.0255	CbGpPWpGaD
Methylphenidate—Cyclopentolate—BCHE—Alzheimer's disease	0.000749	0.351	CrCbGaD
Methylphenidate—SLC6A4—central nervous system—Alzheimer's disease	0.000725	0.0219	CbGeAlD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—SNCA—Alzheimer's disease	0.000703	0.0239	CbGpPWpGaD
Methylphenidate—CYP2D6—forebrain—Alzheimer's disease	0.000669	0.0202	CbGeAlD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—LRRK2—Alzheimer's disease	0.000666	0.0226	CbGpPWpGaD
Methylphenidate—SLC6A2—nervous system—Alzheimer's disease	0.000663	0.0201	CbGeAlD
Methylphenidate—SLC6A2—Monoamine Transport—PVRL2—Alzheimer's disease	0.000645	0.0219	CbGpPWpGaD
Methylphenidate—SLC6A2—central nervous system—Alzheimer's disease	0.000639	0.0193	CbGeAlD
Methylphenidate—Dexmethylphenidate—SLC6A4—Alzheimer's disease	0.000633	0.296	CrCbGaD
Methylphenidate—SLC6A3—brain—Alzheimer's disease	0.000628	0.019	CbGeAlD
Methylphenidate—CYP2D6—telencephalon—Alzheimer's disease	0.000615	0.0186	CbGeAlD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—SNCA—Alzheimer's disease	0.000597	0.0203	CbGpPWpGaD
Methylphenidate—SLC6A4—brain—Alzheimer's disease	0.000576	0.0174	CbGeAlD
Methylphenidate—SLC6A3—Monoamine Transport—PVRL2—Alzheimer's disease	0.000572	0.0194	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—ACHE—Alzheimer's disease	0.000562	0.0191	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—MAOB—Alzheimer's disease	0.000543	0.0184	CbGpPWpGaD
Methylphenidate—SLC6A2—brain—Alzheimer's disease	0.000507	0.0153	CbGeAlD
Methylphenidate—SLC6A2—Monoamine Transport—ACHE—Alzheimer's disease	0.000483	0.0164	CbGpPWpGaD
Methylphenidate—Dexmethylphenidate—CYP2D6—Alzheimer's disease	0.000445	0.208	CrCbGaD
Methylphenidate—SLC6A2—Monoamine Transport—SLC6A4—Alzheimer's disease	0.000444	0.0151	CbGpPWpGaD
Methylphenidate—SLC6A4—Serotonin Transporter Activity—IL1B—Alzheimer's disease	0.000441	0.015	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A6—Alzheimer's disease	0.000429	0.0146	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—ACHE—Alzheimer's disease	0.000428	0.0145	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—PTK2B—Alzheimer's disease	0.000404	0.0137	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—SLC6A4—Alzheimer's disease	0.000393	0.0134	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—MAP2—Alzheimer's disease	0.000387	0.0131	CbGpPWpGaD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A6—Alzheimer's disease	0.00038	0.0129	CbGpPWpGaD
Methylphenidate—CYP2D6—nervous system—Alzheimer's disease	0.000363	0.011	CbGeAlD
Methylphenidate—CYP2D6—central nervous system—Alzheimer's disease	0.00035	0.0106	CbGeAlD
Methylphenidate—CYP2D6—cerebellum—Alzheimer's disease	0.000342	0.0103	CbGeAlD
Methylphenidate—Ipratropium bromide—CYP2D6—Alzheimer's disease	0.000308	0.144	CrCbGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—MAP2—Alzheimer's disease	0.000282	0.00959	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC24A4—Alzheimer's disease	0.000281	0.00954	CbGpPWpGaD
Methylphenidate—CYP2D6—brain—Alzheimer's disease	0.000278	0.00839	CbGeAlD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP46A1—Alzheimer's disease	0.000251	0.00854	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC24A4—Alzheimer's disease	0.000249	0.00845	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP46A1—Alzheimer's disease	0.000248	0.00843	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CHRNA7—Alzheimer's disease	0.00024	0.00815	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TP73—Alzheimer's disease	0.00024	0.00815	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—YWHAQ—Alzheimer's disease	0.000233	0.0079	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—Alzheimer's disease	0.000229	0.00777	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—ACHE—Alzheimer's disease	0.000217	0.00737	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC18A3—Alzheimer's disease	0.000213	0.00723	CbGpPWpGaD
Methylphenidate—Bradycardia—Rivastigmine—Alzheimer's disease	0.000207	0.000961	CcSEcCtD
Methylphenidate—Hallucination—Memantine—Alzheimer's disease	0.000206	0.00096	CcSEcCtD
Methylphenidate—Shock—Galantamine—Alzheimer's disease	0.000206	0.000959	CcSEcCtD
Methylphenidate—Pharyngitis—Memantine—Alzheimer's disease	0.000206	0.000958	CcSEcCtD
Methylphenidate—Nervous system disorder—Galantamine—Alzheimer's disease	0.000205	0.000955	CcSEcCtD
Methylphenidate—Thrombocytopenia—Galantamine—Alzheimer's disease	0.000205	0.000954	CcSEcCtD
Methylphenidate—Chills—Donepezil—Alzheimer's disease	0.000205	0.000954	CcSEcCtD
Methylphenidate—Urinary tract disorder—Memantine—Alzheimer's disease	0.000205	0.000953	CcSEcCtD
Methylphenidate—Tachycardia—Galantamine—Alzheimer's disease	0.000205	0.000951	CcSEcCtD
Methylphenidate—Arrhythmia—Donepezil—Alzheimer's disease	0.000204	0.000949	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CHAT—Alzheimer's disease	0.000204	0.00693	CbGpPWpGaD
Methylphenidate—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000204	0.000949	CcSEcCtD
Methylphenidate—Connective tissue disorder—Memantine—Alzheimer's disease	0.000204	0.000948	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP46A1—Alzheimer's disease	0.000204	0.00692	CbGpPWpGaD
Methylphenidate—Rhinitis—Rivastigmine—Alzheimer's disease	0.000204	0.000946	CcSEcCtD
Methylphenidate—Skin disorder—Galantamine—Alzheimer's disease	0.000204	0.000946	CcSEcCtD
Methylphenidate—Urethral disorder—Memantine—Alzheimer's disease	0.000203	0.000946	CcSEcCtD
Methylphenidate—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000203	0.000944	CcSEcCtD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—Alzheimer's disease	0.000203	0.00688	CbGpPWpGaD
Methylphenidate—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000203	0.000942	CcSEcCtD
Methylphenidate—Hallucination—Rivastigmine—Alzheimer's disease	0.000202	0.000939	CcSEcCtD
Methylphenidate—Alopecia—Donepezil—Alzheimer's disease	0.000202	0.000939	CcSEcCtD
Methylphenidate—Pharyngitis—Rivastigmine—Alzheimer's disease	0.000202	0.000937	CcSEcCtD
Methylphenidate—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000201	0.000932	CcSEcCtD
Methylphenidate—Mental disorder—Donepezil—Alzheimer's disease	0.0002	0.000931	CcSEcCtD
Methylphenidate—Visual impairment—Memantine—Alzheimer's disease	0.0002	0.00093	CcSEcCtD
Methylphenidate—Anorexia—Galantamine—Alzheimer's disease	0.0002	0.000929	CcSEcCtD
Methylphenidate—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.0002	0.000928	CcSEcCtD
Methylphenidate—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000199	0.000925	CcSEcCtD
Methylphenidate—Erythema—Donepezil—Alzheimer's disease	0.000199	0.000925	CcSEcCtD
Methylphenidate—Malnutrition—Donepezil—Alzheimer's disease	0.000199	0.000925	CcSEcCtD
Methylphenidate—Erythema multiforme—Memantine—Alzheimer's disease	0.000196	0.000912	CcSEcCtD
Methylphenidate—Visual impairment—Rivastigmine—Alzheimer's disease	0.000196	0.00091	CcSEcCtD
Methylphenidate—Tension—Donepezil—Alzheimer's disease	0.000195	0.000908	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC30A6—Alzheimer's disease	0.000195	0.00661	CbGpPWpGaD
Methylphenidate—Eye disorder—Memantine—Alzheimer's disease	0.000194	0.000902	CcSEcCtD
Methylphenidate—Nervousness—Donepezil—Alzheimer's disease	0.000193	0.000899	CcSEcCtD
Methylphenidate—Flushing—Memantine—Alzheimer's disease	0.000193	0.000896	CcSEcCtD
Methylphenidate—Cardiac disorder—Memantine—Alzheimer's disease	0.000193	0.000896	CcSEcCtD
Methylphenidate—Back pain—Donepezil—Alzheimer's disease	0.000192	0.000895	CcSEcCtD
Methylphenidate—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000192	0.000893	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HSPD1—Alzheimer's disease	0.000192	0.00652	CbGpPWpGaD
Methylphenidate—Muscle spasms—Donepezil—Alzheimer's disease	0.000191	0.000889	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000191	0.000888	CcSEcCtD
Methylphenidate—Eye disorder—Rivastigmine—Alzheimer's disease	0.00019	0.000882	CcSEcCtD
Methylphenidate—Insomnia—Galantamine—Alzheimer's disease	0.00019	0.000881	CcSEcCtD
Methylphenidate—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000188	0.000876	CcSEcCtD
Methylphenidate—Flushing—Rivastigmine—Alzheimer's disease	0.000188	0.000876	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—GAPDH—Alzheimer's disease	0.000188	0.0064	CbGpPWpGaD
Methylphenidate—Angiopathy—Memantine—Alzheimer's disease	0.000188	0.000875	CcSEcCtD
Methylphenidate—Paraesthesia—Galantamine—Alzheimer's disease	0.000188	0.000875	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—IL1B—Alzheimer's disease	0.000188	0.00638	CbGpPWpGaD
Methylphenidate—Vision blurred—Donepezil—Alzheimer's disease	0.000188	0.000872	CcSEcCtD
Methylphenidate—Immune system disorder—Memantine—Alzheimer's disease	0.000187	0.000872	CcSEcCtD
Methylphenidate—Mediastinal disorder—Memantine—Alzheimer's disease	0.000187	0.00087	CcSEcCtD
Methylphenidate—Tremor—Donepezil—Alzheimer's disease	0.000186	0.000867	CcSEcCtD
Methylphenidate—Somnolence—Galantamine—Alzheimer's disease	0.000186	0.000866	CcSEcCtD
Methylphenidate—Chills—Memantine—Alzheimer's disease	0.000186	0.000866	CcSEcCtD
Methylphenidate—Arrhythmia—Memantine—Alzheimer's disease	0.000185	0.000862	CcSEcCtD
Methylphenidate—Ill-defined disorder—Donepezil—Alzheimer's disease	0.000185	0.000858	CcSEcCtD
Methylphenidate—Dyspepsia—Galantamine—Alzheimer's disease	0.000184	0.000858	CcSEcCtD
Methylphenidate—Angiopathy—Rivastigmine—Alzheimer's disease	0.000184	0.000856	CcSEcCtD
Methylphenidate—Anaemia—Donepezil—Alzheimer's disease	0.000184	0.000855	CcSEcCtD
Methylphenidate—Alopecia—Memantine—Alzheimer's disease	0.000183	0.000853	CcSEcCtD
Methylphenidate—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000183	0.000851	CcSEcCtD
Methylphenidate—Agitation—Donepezil—Alzheimer's disease	0.000183	0.00085	CcSEcCtD
Methylphenidate—Chills—Rivastigmine—Alzheimer's disease	0.000182	0.000847	CcSEcCtD
Methylphenidate—Decreased appetite—Galantamine—Alzheimer's disease	0.000182	0.000847	CcSEcCtD
Methylphenidate—Mental disorder—Memantine—Alzheimer's disease	0.000182	0.000845	CcSEcCtD
Methylphenidate—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000181	0.000843	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000181	0.000841	CcSEcCtD
Methylphenidate—Malnutrition—Memantine—Alzheimer's disease	0.000181	0.00084	CcSEcCtD
Methylphenidate—Fatigue—Galantamine—Alzheimer's disease	0.000181	0.00084	CcSEcCtD
Methylphenidate—Malaise—Donepezil—Alzheimer's disease	0.000179	0.000834	CcSEcCtD
Methylphenidate—Alopecia—Rivastigmine—Alzheimer's disease	0.000179	0.000834	CcSEcCtD
Methylphenidate—Constipation—Galantamine—Alzheimer's disease	0.000179	0.000833	CcSEcCtD
Methylphenidate—Vertigo—Donepezil—Alzheimer's disease	0.000179	0.000831	CcSEcCtD
Methylphenidate—Syncope—Donepezil—Alzheimer's disease	0.000178	0.00083	CcSEcCtD
Methylphenidate—Mental disorder—Rivastigmine—Alzheimer's disease	0.000178	0.000827	CcSEcCtD
Methylphenidate—Tension—Memantine—Alzheimer's disease	0.000177	0.000824	CcSEcCtD
Methylphenidate—Malnutrition—Rivastigmine—Alzheimer's disease	0.000177	0.000822	CcSEcCtD
Methylphenidate—Erythema—Rivastigmine—Alzheimer's disease	0.000177	0.000822	CcSEcCtD
Methylphenidate—Nervousness—Memantine—Alzheimer's disease	0.000175	0.000816	CcSEcCtD
Methylphenidate—Loss of consciousness—Donepezil—Alzheimer's disease	0.000175	0.000813	CcSEcCtD
Methylphenidate—Back pain—Memantine—Alzheimer's disease	0.000175	0.000813	CcSEcCtD
Methylphenidate—Cough—Donepezil—Alzheimer's disease	0.000174	0.000807	CcSEcCtD
Methylphenidate—Tension—Rivastigmine—Alzheimer's disease	0.000173	0.000806	CcSEcCtD
Methylphenidate—Feeling abnormal—Galantamine—Alzheimer's disease	0.000173	0.000803	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC30A6—Alzheimer's disease	0.000172	0.00586	CbGpPWpGaD
Methylphenidate—Convulsion—Donepezil—Alzheimer's disease	0.000172	0.000802	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—Alzheimer's disease	0.000172	0.00585	CbGpPWpGaD
Methylphenidate—Hypertension—Donepezil—Alzheimer's disease	0.000172	0.000799	CcSEcCtD
Methylphenidate—Nervousness—Rivastigmine—Alzheimer's disease	0.000172	0.000798	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000171	0.000797	CcSEcCtD
Methylphenidate—Back pain—Rivastigmine—Alzheimer's disease	0.000171	0.000795	CcSEcCtD
Methylphenidate—Vision blurred—Memantine—Alzheimer's disease	0.00017	0.000792	CcSEcCtD
Methylphenidate—Muscle spasms—Rivastigmine—Alzheimer's disease	0.00017	0.00079	CcSEcCtD
Methylphenidate—Chest pain—Donepezil—Alzheimer's disease	0.000169	0.000788	CcSEcCtD
Methylphenidate—Arthralgia—Donepezil—Alzheimer's disease	0.000169	0.000788	CcSEcCtD
Methylphenidate—Myalgia—Donepezil—Alzheimer's disease	0.000169	0.000788	CcSEcCtD
Methylphenidate—Tremor—Memantine—Alzheimer's disease	0.000169	0.000787	CcSEcCtD
Methylphenidate—Anxiety—Donepezil—Alzheimer's disease	0.000169	0.000785	CcSEcCtD
Methylphenidate—Ill-defined disorder—Memantine—Alzheimer's disease	0.000168	0.000779	CcSEcCtD
Methylphenidate—Discomfort—Donepezil—Alzheimer's disease	0.000167	0.000778	CcSEcCtD
Methylphenidate—Anaemia—Memantine—Alzheimer's disease	0.000167	0.000776	CcSEcCtD
Methylphenidate—Vision blurred—Rivastigmine—Alzheimer's disease	0.000167	0.000774	CcSEcCtD
Methylphenidate—Agitation—Memantine—Alzheimer's disease	0.000166	0.000772	CcSEcCtD
Methylphenidate—Dry mouth—Donepezil—Alzheimer's disease	0.000166	0.00077	CcSEcCtD
Methylphenidate—Abdominal pain—Galantamine—Alzheimer's disease	0.000166	0.00077	CcSEcCtD
Methylphenidate—Body temperature increased—Galantamine—Alzheimer's disease	0.000166	0.00077	CcSEcCtD
Methylphenidate—Tremor—Rivastigmine—Alzheimer's disease	0.000166	0.00077	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—APOD—Alzheimer's disease	0.000166	0.00562	CbGpPWpGaD
Methylphenidate—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000164	0.000762	CcSEcCtD
Methylphenidate—Confusional state—Donepezil—Alzheimer's disease	0.000164	0.000761	CcSEcCtD
Methylphenidate—Anaemia—Rivastigmine—Alzheimer's disease	0.000163	0.00076	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—SLC18A3—Alzheimer's disease	0.000163	0.00554	CbGpPWpGaD
Methylphenidate—Malaise—Memantine—Alzheimer's disease	0.000163	0.000758	CcSEcCtD
Methylphenidate—Agitation—Rivastigmine—Alzheimer's disease	0.000162	0.000755	CcSEcCtD
Methylphenidate—Oedema—Donepezil—Alzheimer's disease	0.000162	0.000755	CcSEcCtD
Methylphenidate—Vertigo—Memantine—Alzheimer's disease	0.000162	0.000755	CcSEcCtD
Methylphenidate—Syncope—Memantine—Alzheimer's disease	0.000162	0.000753	CcSEcCtD
Methylphenidate—Leukopenia—Memantine—Alzheimer's disease	0.000162	0.000752	CcSEcCtD
Methylphenidate—SLC6A2—Monoamine Transport—IL1B—Alzheimer's disease	0.000161	0.00548	CbGpPWpGaD
Methylphenidate—Infection—Donepezil—Alzheimer's disease	0.000161	0.00075	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCA7—Alzheimer's disease	0.00016	0.00544	CbGpPWpGaD
Methylphenidate—Shock—Donepezil—Alzheimer's disease	0.00016	0.000743	CcSEcCtD
Methylphenidate—Palpitations—Memantine—Alzheimer's disease	0.00016	0.000742	CcSEcCtD
Methylphenidate—Malaise—Rivastigmine—Alzheimer's disease	0.000159	0.000741	CcSEcCtD
Methylphenidate—Nervous system disorder—Donepezil—Alzheimer's disease	0.000159	0.00074	CcSEcCtD
Methylphenidate—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000159	0.000739	CcSEcCtD
Methylphenidate—Vertigo—Rivastigmine—Alzheimer's disease	0.000159	0.000738	CcSEcCtD
Methylphenidate—Loss of consciousness—Memantine—Alzheimer's disease	0.000159	0.000738	CcSEcCtD
Methylphenidate—Syncope—Rivastigmine—Alzheimer's disease	0.000158	0.000737	CcSEcCtD
Methylphenidate—Cough—Memantine—Alzheimer's disease	0.000158	0.000733	CcSEcCtD
Methylphenidate—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000157	0.00073	CcSEcCtD
Methylphenidate—Convulsion—Memantine—Alzheimer's disease	0.000157	0.000728	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—Alzheimer's disease	0.000156	0.00531	CbGpPWpGaD
Methylphenidate—Palpitations—Rivastigmine—Alzheimer's disease	0.000156	0.000726	CcSEcCtD
Methylphenidate—Hypertension—Memantine—Alzheimer's disease	0.000156	0.000725	CcSEcCtD
Methylphenidate—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000155	0.000722	CcSEcCtD
Methylphenidate—Anorexia—Donepezil—Alzheimer's disease	0.000155	0.00072	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TF—Alzheimer's disease	0.000155	0.00525	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Galantamine—Alzheimer's disease	0.000154	0.000718	CcSEcCtD
Methylphenidate—Cough—Rivastigmine—Alzheimer's disease	0.000154	0.000717	CcSEcCtD
Methylphenidate—Arthralgia—Memantine—Alzheimer's disease	0.000154	0.000715	CcSEcCtD
Methylphenidate—Chest pain—Memantine—Alzheimer's disease	0.000154	0.000715	CcSEcCtD
Methylphenidate—Myalgia—Memantine—Alzheimer's disease	0.000154	0.000715	CcSEcCtD
Methylphenidate—Anxiety—Memantine—Alzheimer's disease	0.000153	0.000713	CcSEcCtD
Methylphenidate—Convulsion—Rivastigmine—Alzheimer's disease	0.000153	0.000712	CcSEcCtD
Methylphenidate—Hypertension—Rivastigmine—Alzheimer's disease	0.000153	0.000709	CcSEcCtD
Methylphenidate—Discomfort—Memantine—Alzheimer's disease	0.000152	0.000707	CcSEcCtD
Methylphenidate—Arthralgia—Rivastigmine—Alzheimer's disease	0.00015	0.0007	CcSEcCtD
Methylphenidate—Chest pain—Rivastigmine—Alzheimer's disease	0.00015	0.0007	CcSEcCtD
Methylphenidate—Myalgia—Rivastigmine—Alzheimer's disease	0.00015	0.0007	CcSEcCtD
Methylphenidate—Dry mouth—Memantine—Alzheimer's disease	0.00015	0.000699	CcSEcCtD
Methylphenidate—Asthenia—Galantamine—Alzheimer's disease	0.00015	0.000699	CcSEcCtD
Methylphenidate—Anxiety—Rivastigmine—Alzheimer's disease	0.00015	0.000697	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIK1—Alzheimer's disease	0.00015	0.00509	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNA7—Alzheimer's disease	0.00015	0.00509	CbGpPWpGaD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000149	0.000695	CcSEcCtD
Methylphenidate—Confusional state—Memantine—Alzheimer's disease	0.000149	0.000691	CcSEcCtD
Methylphenidate—Discomfort—Rivastigmine—Alzheimer's disease	0.000149	0.000691	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.000148	0.000688	CcSEcCtD
Methylphenidate—Oedema—Memantine—Alzheimer's disease	0.000147	0.000686	CcSEcCtD
Methylphenidate—Dry mouth—Rivastigmine—Alzheimer's disease	0.000147	0.000684	CcSEcCtD
Methylphenidate—Insomnia—Donepezil—Alzheimer's disease	0.000147	0.000683	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—APOD—Alzheimer's disease	0.000147	0.00498	CbGpPWpGaD
Methylphenidate—Infection—Memantine—Alzheimer's disease	0.000146	0.000681	CcSEcCtD
Methylphenidate—Paraesthesia—Donepezil—Alzheimer's disease	0.000146	0.000678	CcSEcCtD
Methylphenidate—Confusional state—Rivastigmine—Alzheimer's disease	0.000145	0.000676	CcSEcCtD
Methylphenidate—Shock—Memantine—Alzheimer's disease	0.000145	0.000674	CcSEcCtD
Methylphenidate—Dyspnoea—Donepezil—Alzheimer's disease	0.000145	0.000673	CcSEcCtD
Methylphenidate—Nervous system disorder—Memantine—Alzheimer's disease	0.000145	0.000672	CcSEcCtD
Methylphenidate—Somnolence—Donepezil—Alzheimer's disease	0.000144	0.000671	CcSEcCtD
Methylphenidate—Thrombocytopenia—Memantine—Alzheimer's disease	0.000144	0.000671	CcSEcCtD
Methylphenidate—Oedema—Rivastigmine—Alzheimer's disease	0.000144	0.000671	CcSEcCtD
Methylphenidate—Tachycardia—Memantine—Alzheimer's disease	0.000144	0.000669	CcSEcCtD
Methylphenidate—Diarrhoea—Galantamine—Alzheimer's disease	0.000143	0.000667	CcSEcCtD
Methylphenidate—Infection—Rivastigmine—Alzheimer's disease	0.000143	0.000666	CcSEcCtD
Methylphenidate—Skin disorder—Memantine—Alzheimer's disease	0.000143	0.000666	CcSEcCtD
Methylphenidate—SLC6A3—Monoamine Transport—IL1B—Alzheimer's disease	0.000143	0.00486	CbGpPWpGaD
Methylphenidate—Dyspepsia—Donepezil—Alzheimer's disease	0.000143	0.000665	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC24A4—Alzheimer's disease	0.000143	0.00485	CbGpPWpGaD
Methylphenidate—Hyperhidrosis—Memantine—Alzheimer's disease	0.000143	0.000663	CcSEcCtD
Methylphenidate—Shock—Rivastigmine—Alzheimer's disease	0.000142	0.00066	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCA7—Alzheimer's disease	0.000142	0.00482	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NTRK2—Alzheimer's disease	0.000141	0.00481	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—SST—Alzheimer's disease	0.000141	0.00481	CbGpPWpGaD
Methylphenidate—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000141	0.000658	CcSEcCtD
Methylphenidate—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000141	0.000657	CcSEcCtD
Methylphenidate—Decreased appetite—Donepezil—Alzheimer's disease	0.000141	0.000656	CcSEcCtD
Methylphenidate—Tachycardia—Rivastigmine—Alzheimer's disease	0.000141	0.000655	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—CHRNB2—Alzheimer's disease	0.000141	0.00478	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CST3—Alzheimer's disease	0.000141	0.00478	CbGpPWpGaD
Methylphenidate—Anorexia—Memantine—Alzheimer's disease	0.000141	0.000653	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.00014	0.000652	CcSEcCtD
Methylphenidate—Skin disorder—Rivastigmine—Alzheimer's disease	0.00014	0.000651	CcSEcCtD
Methylphenidate—Fatigue—Donepezil—Alzheimer's disease	0.00014	0.000651	CcSEcCtD
Methylphenidate—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000139	0.000648	CcSEcCtD
Methylphenidate—Constipation—Donepezil—Alzheimer's disease	0.000139	0.000646	CcSEcCtD
Methylphenidate—Pain—Donepezil—Alzheimer's disease	0.000139	0.000646	CcSEcCtD
Methylphenidate—Dizziness—Galantamine—Alzheimer's disease	0.000139	0.000644	CcSEcCtD
Methylphenidate—Anorexia—Rivastigmine—Alzheimer's disease	0.000137	0.000639	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—TNF—Alzheimer's disease	0.000136	0.00463	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000134	0.000625	CcSEcCtD
Methylphenidate—Feeling abnormal—Donepezil—Alzheimer's disease	0.000134	0.000622	CcSEcCtD
Methylphenidate—Insomnia—Memantine—Alzheimer's disease	0.000133	0.00062	CcSEcCtD
Methylphenidate—Vomiting—Galantamine—Alzheimer's disease	0.000133	0.000619	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000133	0.000617	CcSEcCtD
Methylphenidate—Paraesthesia—Memantine—Alzheimer's disease	0.000132	0.000616	CcSEcCtD
Methylphenidate—Rash—Galantamine—Alzheimer's disease	0.000132	0.000614	CcSEcCtD
Methylphenidate—Dermatitis—Galantamine—Alzheimer's disease	0.000132	0.000614	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—SLC6A4—Alzheimer's disease	0.000132	0.00448	CbGpPWpGaD
Methylphenidate—Dyspnoea—Memantine—Alzheimer's disease	0.000131	0.000611	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000131	0.000611	CcSEcCtD
Methylphenidate—Headache—Galantamine—Alzheimer's disease	0.000131	0.00061	CcSEcCtD
Methylphenidate—Somnolence—Memantine—Alzheimer's disease	0.000131	0.000609	CcSEcCtD
Methylphenidate—Insomnia—Rivastigmine—Alzheimer's disease	0.00013	0.000607	CcSEcCtD
Methylphenidate—Dyspepsia—Memantine—Alzheimer's disease	0.00013	0.000603	CcSEcCtD
Methylphenidate—Paraesthesia—Rivastigmine—Alzheimer's disease	0.00013	0.000602	CcSEcCtD
Methylphenidate—Urticaria—Donepezil—Alzheimer's disease	0.000129	0.0006	CcSEcCtD
Methylphenidate—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000129	0.000598	CcSEcCtD
Methylphenidate—Body temperature increased—Donepezil—Alzheimer's disease	0.000128	0.000597	CcSEcCtD
Methylphenidate—Abdominal pain—Donepezil—Alzheimer's disease	0.000128	0.000597	CcSEcCtD
Methylphenidate—Somnolence—Rivastigmine—Alzheimer's disease	0.000128	0.000596	CcSEcCtD
Methylphenidate—Decreased appetite—Memantine—Alzheimer's disease	0.000128	0.000596	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—CRH—Alzheimer's disease	0.000128	0.00434	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHAT—Alzheimer's disease	0.000127	0.00433	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIK2—Alzheimer's disease	0.000127	0.00433	CbGpPWpGaD
Methylphenidate—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000127	0.000592	CcSEcCtD
Methylphenidate—Fatigue—Memantine—Alzheimer's disease	0.000127	0.000591	CcSEcCtD
Methylphenidate—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000127	0.00059	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC24A4—Alzheimer's disease	0.000126	0.0043	CbGpPWpGaD
Methylphenidate—Constipation—Memantine—Alzheimer's disease	0.000126	0.000586	CcSEcCtD
Methylphenidate—Pain—Memantine—Alzheimer's disease	0.000126	0.000586	CcSEcCtD
Methylphenidate—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000125	0.000583	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000125	0.000579	CcSEcCtD
Methylphenidate—Nausea—Galantamine—Alzheimer's disease	0.000124	0.000579	CcSEcCtD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—Alzheimer's disease	0.000124	0.00423	CbGpPWpGaD
Methylphenidate—Fatigue—Rivastigmine—Alzheimer's disease	0.000124	0.000578	CcSEcCtD
Methylphenidate—Constipation—Rivastigmine—Alzheimer's disease	0.000123	0.000574	CcSEcCtD
Methylphenidate—Pain—Rivastigmine—Alzheimer's disease	0.000123	0.000574	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—MAOB—Alzheimer's disease	0.000122	0.00413	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Memantine—Alzheimer's disease	0.000122	0.000565	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—NPS—Alzheimer's disease	0.000121	0.00411	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000121	0.000561	CcSEcCtD
Methylphenidate—Hypersensitivity—Donepezil—Alzheimer's disease	0.00012	0.000556	CcSEcCtD
Methylphenidate—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000119	0.000553	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000118	0.000548	CcSEcCtD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—Alzheimer's disease	0.000117	0.00398	CbGpPWpGaD
Methylphenidate—Urticaria—Memantine—Alzheimer's disease	0.000117	0.000545	CcSEcCtD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—TGFB1—Alzheimer's disease	0.000117	0.00398	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC6A4—Alzheimer's disease	0.000117	0.00397	CbGpPWpGaD
Methylphenidate—Body temperature increased—Memantine—Alzheimer's disease	0.000117	0.000542	CcSEcCtD
Methylphenidate—Abdominal pain—Memantine—Alzheimer's disease	0.000117	0.000542	CcSEcCtD
Methylphenidate—Asthenia—Donepezil—Alzheimer's disease	0.000117	0.000542	CcSEcCtD
Methylphenidate—Pruritus—Donepezil—Alzheimer's disease	0.000115	0.000534	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—GRIK1—Alzheimer's disease	0.000115	0.0039	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNA7—Alzheimer's disease	0.000115	0.0039	CbGpPWpGaD
Methylphenidate—Urticaria—Rivastigmine—Alzheimer's disease	0.000115	0.000533	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—CALM1—Alzheimer's disease	0.000114	0.00388	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HMOX1—Alzheimer's disease	0.000114	0.00388	CbGpPWpGaD
Methylphenidate—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000114	0.00053	CcSEcCtD
Methylphenidate—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000114	0.00053	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—APOE—Alzheimer's disease	0.000114	0.00386	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIA1—Alzheimer's disease	0.000114	0.00386	CbGpPWpGaD
Methylphenidate—Diarrhoea—Donepezil—Alzheimer's disease	0.000111	0.000517	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—PPARGC1A—Alzheimer's disease	0.000109	0.00369	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Memantine—Alzheimer's disease	0.000109	0.000505	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP46A1—Alzheimer's disease	0.000108	0.00368	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNB2—Alzheimer's disease	0.000108	0.00365	CbGpPWpGaD
Methylphenidate—Dizziness—Donepezil—Alzheimer's disease	0.000107	0.000499	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP46A1—Alzheimer's disease	0.000107	0.00363	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000106	0.000494	CcSEcCtD
Methylphenidate—Asthenia—Memantine—Alzheimer's disease	0.000106	0.000492	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—BDNF—Alzheimer's disease	0.000106	0.00359	CbGpPWpGaD
Methylphenidate—Pruritus—Memantine—Alzheimer's disease	0.000104	0.000485	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—CP—Alzheimer's disease	0.000104	0.00353	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—Alzheimer's disease	0.000104	0.00353	CbGpPWpGaD
Methylphenidate—Asthenia—Rivastigmine—Alzheimer's disease	0.000103	0.000481	CcSEcCtD
Methylphenidate—Vomiting—Donepezil—Alzheimer's disease	0.000103	0.00048	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—AGER—Alzheimer's disease	0.000103	0.00348	CbGpPWpGaD
Methylphenidate—Rash—Donepezil—Alzheimer's disease	0.000102	0.000476	CcSEcCtD
Methylphenidate—Dermatitis—Donepezil—Alzheimer's disease	0.000102	0.000476	CcSEcCtD
Methylphenidate—Pruritus—Rivastigmine—Alzheimer's disease	0.000102	0.000474	CcSEcCtD
Methylphenidate—Headache—Donepezil—Alzheimer's disease	0.000102	0.000473	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL1A—Alzheimer's disease	0.000101	0.00344	CbGpPWpGaD
Methylphenidate—Diarrhoea—Memantine—Alzheimer's disease	0.000101	0.000469	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—NGFR—Alzheimer's disease	9.91e-05	0.00337	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC30A6—Alzheimer's disease	9.89e-05	0.00336	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—ACHE—Alzheimer's disease	9.88e-05	0.00336	CbGpPWpGaD
Methylphenidate—Diarrhoea—Rivastigmine—Alzheimer's disease	9.87e-05	0.000459	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—GSK3B—Alzheimer's disease	9.85e-05	0.00335	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HMOX1—Alzheimer's disease	9.81e-05	0.00333	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—MEF2C—Alzheimer's disease	9.81e-05	0.00333	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNA4—Alzheimer's disease	9.77e-05	0.00332	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHAT—Alzheimer's disease	9.77e-05	0.00332	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIK2—Alzheimer's disease	9.77e-05	0.00332	CbGpPWpGaD
Methylphenidate—Dizziness—Memantine—Alzheimer's disease	9.75e-05	0.000453	CcSEcCtD
Methylphenidate—Nausea—Donepezil—Alzheimer's disease	9.65e-05	0.000448	CcSEcCtD
Methylphenidate—Dizziness—Rivastigmine—Alzheimer's disease	9.54e-05	0.000443	CcSEcCtD
Methylphenidate—Vomiting—Memantine—Alzheimer's disease	9.37e-05	0.000436	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NGF—Alzheimer's disease	9.37e-05	0.00318	CbGpPWpGaD
Methylphenidate—Rash—Memantine—Alzheimer's disease	9.3e-05	0.000432	CcSEcCtD
Methylphenidate—Dermatitis—Memantine—Alzheimer's disease	9.29e-05	0.000432	CcSEcCtD
Methylphenidate—Headache—Memantine—Alzheimer's disease	9.24e-05	0.000429	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—Alzheimer's disease	9.21e-05	0.00313	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—CP—Alzheimer's disease	9.21e-05	0.00313	CbGpPWpGaD
Methylphenidate—Vomiting—Rivastigmine—Alzheimer's disease	9.17e-05	0.000426	CcSEcCtD
Methylphenidate—Rash—Rivastigmine—Alzheimer's disease	9.09e-05	0.000423	CcSEcCtD
Methylphenidate—Dermatitis—Rivastigmine—Alzheimer's disease	9.09e-05	0.000422	CcSEcCtD
Methylphenidate—Headache—Rivastigmine—Alzheimer's disease	9.04e-05	0.00042	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Alzheimer's disease	8.92e-05	0.00303	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARGC1A—Alzheimer's disease	8.87e-05	0.00301	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—AGER—Alzheimer's disease	8.81e-05	0.00299	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC30A6—Alzheimer's disease	8.77e-05	0.00298	CbGpPWpGaD
Methylphenidate—Nausea—Memantine—Alzheimer's disease	8.76e-05	0.000407	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—GRIA1—Alzheimer's disease	8.7e-05	0.00296	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HMOX1—Alzheimer's disease	8.69e-05	0.00295	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BCHE—Alzheimer's disease	8.61e-05	0.00292	CbGpPWpGaD
Methylphenidate—Nausea—Rivastigmine—Alzheimer's disease	8.57e-05	0.000398	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—APOD—Alzheimer's disease	8.41e-05	0.00286	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—DLG4—Alzheimer's disease	8.4e-05	0.00285	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNB2—Alzheimer's disease	8.24e-05	0.0028	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIN2B—Alzheimer's disease	8.21e-05	0.00279	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PLCB1—Alzheimer's disease	8.12e-05	0.00276	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PRKCG—Alzheimer's disease	7.86e-05	0.00267	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—AGER—Alzheimer's disease	7.81e-05	0.00265	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ACHE—Alzheimer's disease	7.57e-05	0.00257	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNA4—Alzheimer's disease	7.49e-05	0.00254	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—APOD—Alzheimer's disease	7.45e-05	0.00253	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREB1—Alzheimer's disease	7.13e-05	0.00242	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—LEP—Alzheimer's disease	6.77e-05	0.0023	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BCHE—Alzheimer's disease	6.6e-05	0.00224	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—MAOB—Alzheimer's disease	6.46e-05	0.00219	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—DLG4—Alzheimer's disease	6.44e-05	0.00219	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NOS2—Alzheimer's disease	6.31e-05	0.00214	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIN2B—Alzheimer's disease	6.29e-05	0.00214	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—PLCB1—Alzheimer's disease	6.22e-05	0.00211	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PRKCG—Alzheimer's disease	6.01e-05	0.00204	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARG—Alzheimer's disease	5.9e-05	0.002	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—GSK3B—Alzheimer's disease	5.87e-05	0.00199	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CREB1—Alzheimer's disease	5.82e-05	0.00198	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL1B—Alzheimer's disease	5.29e-05	0.0018	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CP—Alzheimer's disease	5.28e-05	0.00179	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—Alzheimer's disease	5.28e-05	0.00179	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CALM1—Alzheimer's disease	5.2e-05	0.00177	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—PTGS1—Alzheimer's disease	4.89e-05	0.00166	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CP—Alzheimer's disease	4.68e-05	0.00159	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—PRKCG—Alzheimer's disease	4.6e-05	0.00156	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TF—Alzheimer's disease	4.49e-05	0.00153	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—Alzheimer's disease	4.48e-05	0.00152	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CREB1—Alzheimer's disease	4.45e-05	0.00151	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TGFB1—Alzheimer's disease	4.33e-05	0.00147	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CALM1—Alzheimer's disease	3.98e-05	0.00135	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TF—Alzheimer's disease	3.98e-05	0.00135	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—MAPK8—Alzheimer's disease	3.96e-05	0.00134	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—Alzheimer's disease	3.84e-05	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TGFB1—Alzheimer's disease	3.73e-05	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CREB1—Alzheimer's disease	3.41e-05	0.00116	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TGFB1—Alzheimer's disease	3.3e-05	0.00112	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	3.14e-05	0.00107	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6—Alzheimer's disease	3.1e-05	0.00105	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	2.78e-05	0.000945	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—DHCR24—Alzheimer's disease	2.77e-05	0.000942	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—Alzheimer's disease	2.76e-05	0.000938	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—IL6—Alzheimer's disease	2.53e-05	0.000859	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CA4—Alzheimer's disease	2.36e-05	0.000801	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GAPDHS—Alzheimer's disease	2.22e-05	0.000753	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ATP5A1—Alzheimer's disease	2.1e-05	0.000714	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLD3—Alzheimer's disease	2.01e-05	0.000681	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD17B10—Alzheimer's disease	1.92e-05	0.000653	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP46A1—Alzheimer's disease	1.85e-05	0.000629	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ND1—Alzheimer's disease	1.79e-05	0.000607	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TPI1—Alzheimer's disease	1.15e-05	0.000391	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CHAT—Alzheimer's disease	1.15e-05	0.000391	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MAOB—Alzheimer's disease	1.1e-05	0.000375	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GAPDH—Alzheimer's disease	1.06e-05	0.000361	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—A2M—Alzheimer's disease	1.03e-05	0.000349	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACHE—Alzheimer's disease	8.93e-06	0.000303	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	8.83e-06	0.0003	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ENO1—Alzheimer's disease	8.37e-06	0.000284	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	8.37e-06	0.000284	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BCHE—Alzheimer's disease	7.78e-06	0.000264	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	7.34e-06	0.000249	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	7.12e-06	0.000242	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	6.13e-06	0.000208	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	6.11e-06	0.000207	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LPL—Alzheimer's disease	5.59e-06	0.00019	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	5.03e-06	0.000171	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CALM1—Alzheimer's disease	4.7e-06	0.00016	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APOE—Alzheimer's disease	4.68e-06	0.000159	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CAV1—Alzheimer's disease	4.64e-06	0.000158	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARG—Alzheimer's disease	4.08e-06	0.000139	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—INS—Alzheimer's disease	4e-06	0.000136	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NOS3—Alzheimer's disease	3.51e-06	0.000119	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	3.21e-06	0.000109	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—Alzheimer's disease	1.61e-06	5.48e-05	CbGpPWpGaD
